Overview

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

Status:
Completed
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis
Phase:
Phase 2
Details
Lead Sponsor:
Tokyo Medical University